Canaccord Genuity analyst Kyle Rose maintained a Buy rating on SeaSpine Holdings (SPNE) on October 11 and set a price target of $21.00. The company’s shares closed last Tuesday at $15.82, close to its 52-week high of $16.91.
According to TipRanks.com, Rose is a 5-star analyst with an average return of 11.0% and a 53.0% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Smith & Nephew Snats, and Alphatec Holdings.
SeaSpine Holdings has an analyst consensus of Strong Buy, with a price target consensus of $20.00, implying a 29.7% upside from current levels. In a report issued on October 6, Piper Sandler also maintained a Buy rating on the stock with a $18.00 price target.
See today’s analyst top recommended stocks >>
Based on SeaSpine Holdings’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $28.59 million and GAAP net loss of $13.71 million. In comparison, last year the company earned revenue of $39.31 million and had a GAAP net loss of $12.04 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SeaSpine Holdings Corp. is a medical technology company, which focuses on design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. It has a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. The company was founded on February 12, 2015 and is headquartered in Carlsbad, CA.
Read More on SPNE:
